Pablo Uribe

Pablo Uribe

Auto-generated profile, based on publicly available information

Pablo Uribe

Departamento de Dermatología, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2011 in Pathology - Research and Practice
Verified
Journal Article
Closed access
PUPablo Uribe
Pablo Uribe
SGSergio Gonzalez
Sergio Gonzalez

1 October 2003 in The American Journal of Dermatopathology
Verified
Journal Article
Closed access
PUPablo Uribe
Pablo Uribe
IWIgnacio I. Wistuba
Ignacio I. Wistuba
SGSergio González
Sergio González
BRAF mutations have recently been detected with a high frequency (66%) in cutaneous melanoma. All those mutations are activating, with a single substitution (T1796A) at codon 599 (V599E) accounting for over 90%. To investigate the stage in which those mutations occur in the currently proposed sequential malignant transformation of melanocytes, 22 benign melanocytic nevi, 23 melanocytic atypical nevi, and 25 primary cutaneous melanoma from 63 different patients were examined for BRAF mutations using DNA extracted from microdissected formalin-fixed and paraffin-embedded tissues, and a two-round PCR-RFLP-based strategy. A subset of samples was sequenced for mutation confirmation. Sixteen benign (73%) and eleven atypical (52%) melanocytic nevi, and thirteen melanoma (56%) demonstrated BRAF mutations at codon 599, and no statistically significant differences were detected among all three types of lesions. No mutations were demonstrated in microdissected epidermal keratinocytes adjacent to melanocytic lesions having BRAF mutations. No correlation was detected between BRAF mutational status and age, sun exposure, and Clark's level in malignant melanoma. However, comparing only atypical nevi and melanoma lesions the frequency of BRAF mutation is significantly greater in male (78%) than female (35%) patients (P = 0.0194). The previously described T1796A point mutation was detected in 17 of 18 mutated samples, and a novel mutation consisting of a substitution of valine for lysine (GT1795-96AA) was detected in one melanoma case. Our findings of a high frequency of BRAF mutations at codon 599 in benign melanocytic lesions of the skin indicate that this mutation is not sufficient by itself for malignant transformation.

1 July 2015 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
Cristian Navarrete-DechentCristian Navarrete-Dechent
Cristian Navarrete-Dechent
MVMichael J. Veness
Michael J. Veness
NDNicolás Droppelmann
Nicolás Droppelmann
PUPablo Uribe
Pablo Uribe

9 December 2013 in Australasian Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
RARachael Anforth
Rachael Anforth
MLMichael Liu
Michael Liu
BNBao Nguyen
Bao Nguyen
PUPablo Uribe
Pablo Uribe
RKRichard Kefford
Richard Kefford
PFPablo Fernandez-Peñas
Pablo Fernandez-Peñas

1 January 2006 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
PUPablo Uribe
Pablo Uribe
LALeonardo Andrade
Leonardo Andrade
SGSergio Gonzalez
Sergio Gonzalez

2 December 2017 in Experimental Hematology & Oncology
Verified
Journal Article
Open access
PDF file
MMMauricio Sarmiento Maldonado
Mauricio Sarmiento Maldonado
PVPablo Ramírez Villanueva
Pablo Ramírez Villanueva
PCPablo Bertín Cortes-Monroy
Pablo Bertín Cortes-Monroy
VAVeronica Jara Arias
Veronica Jara Arias
KDKatherine Soto Donoso
Katherine Soto Donoso
JPJose A Perez-Simon
Jose A Perez-Simon
Ruxolitinib is a potent inhibitor of JAK1/2 with proven efficacy in myelofibrosis. In recent years, research in graft versus host disease (GVHD) has revealed the role of activation of JAK pathways in alloreactive lymphocytes. Some reports have shown significant responses in refractory GVHD patients. In this report we present our experience in 8 patients with acute or chronic GVHD with refractoriness to steroids and extracorporeal photopheresis treated with ruxolitinib. Three patients had acute GVHD (1 pulmonary, 2 cutaneous, 1 multi-systemic) and 5 had chronic GVHD (3 cutaneous); 85% obtained an overall response and 50% a complete response with a tolerable toxicity profile. In our series, Ruxolitinib was very active as a rescue therapy for patients with acute or chronic GVHD refractory to standard treatment.